Article
Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology - 1 Oct 2011
Huang Wei-Ching, Tsai Cheng-Chieh, Chen Chia-Ling, Chen Tsai-Yun, Chen Ya-Ping, Lin Yee-Shin, Lu Pei-Jung, Lin Chun-Mao, Wang Shwu-Huey, Tsao Chiung-Wen, Wang Chi-Yun, Cheng Yi-Lin, Hsieh Chia-Yuan, Tseng Po-Chun, Lin Chiou-Feng
Abstract excerpt
Inactivation of glycogen synthase kinase (GSK)-3 has been implicated in cancer progression. Previously, we showed an abundance of inactive GSK-3 in the human chronic myeloid leukemia (CML) cell line. CML is a hematopoietic malignancy caused by an oncogenic Bcr-Abl tyrosine kinase. In Bcr-Abl signaling, the role of GSK-3 is not well defined. Here, we report that enforced expression of constitutively active GSK-3...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.